Details for Patent: 11,628,150
✉ Email this page to a colleague
Which drugs does patent 11,628,150 protect, and when does it expire?
Patent 11,628,150 protects GIMOTI and is included in one NDA.
This patent has ten patent family members in seven countries.
Summary for Patent: 11,628,150
| Title: | Nasal formulations of metoclopramide |
| Abstract: | Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof. |
| Inventor(s): | Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden |
| Assignee: | Evoke Pharma Inc |
| Application Number: | US17/100,664 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Drugs Protected by US Patent 11,628,150
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qol Medcl | GIMOTI | metoclopramide hydrochloride | SPRAY, METERED;NASAL | 209388-001 | Jun 19, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,628,150
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2780485 | ⤷ Start Trial | |||
| Canada | 2984736 | ⤷ Start Trial | |||
| Canada | 3155873 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
